AF
PASG icon

Amalgamated Financial’s Passage Bio PASG Stock Holding History

Amalgamated Financial’s Portfolio PASG Stock Details PASG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$14K Buy
+224
New +$18.5K ﹤0.01% 2833

Other funds holding PASG

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HCM
Highline Capital Management New York $53.5M AUM 21.72% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

Amalgamated Financial's PASG Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Passage Bio (PASG) in Q1 2022: 224 shares worth $14K. The stake represents ﹤0.01% of the portfolio and ranks #2833 among its holdings.

108 funds tracked by Wall St. Rank hold PASG as of Q1 2022.

  • Amalgamated Financial held 224 shares of Passage Bio worth $14K as of Q1 2022.
  • Passage Bio was a new Amalgamated Financial position in Q1 2022.
  • Passage Bio made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #2833 holding.
  • 108 funds tracked by Wall St. Rank held Passage Bio as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.